Form 6-K Hutchison China MediTech For: Jun 29
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of June 2018
Commission File Number: 001-37710
HUTCHISON CHINA MEDITECH LIMITED
(Translation of registrant’s name into English)
22/F, Hutchison House, 10 Harcourt Road, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
HUTCHISON CHINA MEDITECH LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. |
|
Description |
|
|
|
Exhibit 99.1 |
|
Announcement relating to notice of 2018 interim results |
Exhibit 99.2 |
|
Announcement relating to blocklisting six monthly return |
Exhibit 99.3 |
|
Announcement relating to total voting rights |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
HUTCHISON CHINA MEDITECH LIMITED |
|
|
|
|
|
|
|
|
By: |
/s/ Johnny Cheng |
|
Name: |
Johnny Cheng |
|
Title: |
Chief Financial Officer |
Date: June 29, 2018
3
Exhibit 99.1
Chi-Med to Announce 2018 Half-Year Financial Results
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST).
An analyst presentation will be held at 9:00 am BST (4:00 pm Hong Kong Time) on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins.
For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (2:00 pm BST).
Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries |
|
Mark Lee, Senior Vice President, |
+852 2121 8200 |
|
|
U.K. & International Media Enquiries |
|
Anthony Carlisle, |
+44 7973 611 888 (Mobile) |
|
|
U.S. Based Media Enquiries |
|
Brad Miles, Solebury Trout |
+1 (917) 570 7340 (Mobile) |
Susan Duffy, Solebury Trout |
+1 (917) 499 8887 (Mobile) |
|
|
Investor Relations |
|
Xuan Yang, Solebury Trout |
+1 (415) 971 9412 (Mobile) |
David Dible, |
+44 7967 566 919 (Mobile) |
|
|
Panmure Gordon (UK) Limited |
|
Richard Gray / Andrew Potts |
+44 (20) 7886 2500 |
Exhibit 99.2
Blocklisting Six Monthly Return
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:
1. |
Name of applicant:
|
|
Hutchison China MediTech Limited |
|
2. |
Name of scheme:
|
|
(a) |
Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2005 (“2005 HCML Share Option Scheme”)
|
|
|
(b) |
Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2015 (“2015 HCML Share Option Scheme”)
|
|
3. |
Period of return:
|
|
From December 29, 2017 to June 28, 2018
|
|
4. |
Balance under scheme from previous return:
|
|
(a) |
2005 HCML Share Option Scheme: 304,999 ordinary shares of US$1 each
|
|
(b) |
2015 HCML Share Option Scheme: 1,000,000 ordinary shares of US$1 each
|
||
5. |
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
|
|
(a) |
2005 HCML Share Option Scheme: Nil
|
(b) |
2015 HCML Share Option Scheme: 1,425,597 ordinary shares of US$1 each |
|||
6. |
Number of securities issued/allotted under scheme during period:
|
|
(a) |
2005 HCML Share Option Scheme: 85,646 ordinary shares of US$1 each
|
|
|
(b) |
2015 HCML Share Option Scheme: Nil ordinary shares of US$1 each
|
|
7. |
Balance under scheme not yet issued/allotted at end of the period:
|
|
(a) |
2005 HCML Share Option Scheme: 219,353 ordinary shares of US$1 each
|
|
|
(b) |
2015 HCML Share Option Scheme: 2,425,597 ordinary shares of US$1 each
|
|
8. |
Number and class of securities originally listed and the date of admission:
|
|
(i) |
2,560,606 ordinary shares of US$1 each admitted on June 26, 2007
|
(ii) |
1,000,000 ordinary shares of US$1 each admitted on June 20, 2016 |
|||
|
|
(iii) |
1,425,597 ordinary shares of US$1 each admitted on April 27, 2018
|
|
9. |
Total number of securities in issue at the end of the period:
|
|
66,532,683 ordinary shares of US$1 each |
|
Name of contact:
|
|
Christian Hogg |
||
Address of contact:
|
|
21/F., Hutchison House, 10 Harcourt Road, Hong Kong
|
||
Telephone number of contact: |
|
+852 2121 8200 |
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries |
|
Mark Lee, Senior Vice President, |
+852 2121 8200 |
|
|
U.K. & International Media Enquiries |
|
Anthony Carlisle, |
+44 7973 611 888 (Mobile) |
|
|
U.S. Based Media Enquiries |
|
Brad Miles, Solebury Trout |
+1 (917) 570 7340 (Mobile) |
Susan Duffy, Solebury Trout |
+1 (917) 499 8887 (Mobile) |
Investor Relations |
|
Xuan Yang, Solebury Trout |
+1 (415) 971 9412 (Mobile) |
David Dible, |
+44 7967 566 919 (Mobile) |
|
|
Panmure Gordon (UK) Limited |
|
Richard Gray / Andrew Potts |
+44 (20) 7886 2500 |
Exhibit 99.3
Total Voting Rights
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 29, 2018, the issued share capital of Chi-Med consisted of 66,532,683 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.
The above figure of 66,532,683 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.
For illustrative purposes only, the 66,532,683 ordinary shares would be equivalent to 66,532,683 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 133,065,366 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries |
|
Mark Lee, Senior Vice President, |
+852 2121 8200 |
|
|
U.K. & International Media Enquiries |
|
Anthony Carlisle, |
+44 7973 611 888 (Mobile) |
|
|
U.S. Based Media Enquiries |
|
Brad Miles, Solebury Trout |
+1 (917) 570 7340 (Mobile) |
Susan Duffy, Solebury Trout |
+1 (917) 499 8887 (Mobile) |
|
|
Investor Relations |
|
Xuan Yang, Solebury Trout |
+1 (415) 971 9412 (Mobile) |
David Dible, |
+44 7967 566 919 (Mobile) |
|
|
Panmure Gordon (UK) Limited |
|
Richard Gray / Andrew Potts |
+44 (20) 7886 2500 |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Form 8.3 - ABRDN European Logistics Income Plc
- Flash News: OKX to Give Away 150 Nervape Bonelist NFT Spots
- Linde to Increase Green Hydrogen Production in Brazil
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!